Microneedle Array for Painless Bioactive Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods of administering treatments to the human body are limited, often causing pain, bruising, and gastrointestinal side effects, and do not efficiently deliver bioactive agents to their target locations without diminishing their biological activity.
Innovation Solution
The Aquagold Technology (AQT) method, which involves delivering therapeutic, nutraceutical, and aesthetic compounds directly into the skin layers using a micro transjection-like approach, avoiding hepatic, renal, or gastrointestinal filtration and absorption, thereby ensuring bioactive agents reach their target location without extraneous factors affecting their activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional injection methods are used to deliver bioactive agents, then delivery efficiency is improved, but pain, bruising, and bleeding occur
Solution Approach 1:
The injection device is segmented into multiple fine needles arranged in an array, allowing distributed delivery of bioactive agents across multiple injection sites. This segmentation reduces the trauma caused by each individual needle while maintaining overall delivery efficiency through parallel injection pathways.
Solution Approach 2:
The needle array is designed with varying needle lengths, angles, and depths to match the specific anatomical requirements of different treatment areas. This local customization optimizes delivery efficiency for each region while minimizing harmful effects by adapting to local tissue characteristics.
2Ease of operation
If oral administration is used to deliver bioactive agents, then ease of administration is improved, but gastrointestinal filtration and absorption diminish biological activity
Solution Approach 1:
The invention extracts the bioactive agents from the gastrointestinal environment entirely by delivering them directly into the dermal layer through injection. This eliminates the harmful filtration and absorption processes that occur in the digestive system while preserving the full biological activity of the compounds.
Solution Approach 2:
The dermal layer serves as an intermediary delivery route that bypasses the gastrointestinal system. By injecting bioactive agents directly into the skin, the invention uses the dermis as a mediator to transport compounds systemically without exposing them to digestive enzymes and filtration mechanisms.
3Object-affected harmful factors
If topical application is used to deliver bioactive agents, then non-invasiveness is improved, but efficacy and bioactivity are significantly reduced
Solution Approach 1:
The invention uses a partial injection approach where only the epidermal and dermal layers are penetrated, stopping before reaching deeper subcutaneous tissues. This partial action maintains non-invasiveness while achieving sufficient efficacy by delivering bioactive agents directly to the target skin layers where they can be absorbed systemically.
Solution Approach 2:
The invention transitions from two-dimensional topical surface application to three-dimensional subcutaneous injection. By moving the delivery method into the depth dimension of the skin, the invention achieves significantly improved bioactivity and efficacy while maintaining relative non-invasiveness through shallow needle penetration.
4Object-affected harmful factors
If micro needle patches are used to deliver bioactive agents, then pain reduction is improved, but onset of delivery is delayed and aesthetic limitations exist
Solution Approach 1:
The injection device uses dynamic needle penetration where the needles are inserted at controlled speeds and depths, adjusting in real-time based on tissue resistance and treatment requirements. This dynamic approach maintains pain reduction while achieving rapid onset of delivery by optimizing penetration parameters during the procedure.
Solution Approach 2:
The invention uses rapid needle insertion that quickly penetrates the epidermal barrier and delivers bioactive agents directly into the dermal layer. This rushing through the skin barrier minimizes the time agents are exposed to degradation and accelerates onset of delivery while keeping the procedure brief enough to minimize patient discomfort.
Data Source
AI summary
The embodiments relate to improved skin quality, health and appearance using a new delivery method and certain bioactive compositions and formulations. The system incorporates microneedle delivery technology with unique compositions and formulations. Such development allows for the pursuit of personalized medicine, or treatment delivery that can expand to remote controlled environment, immediate compounding and ultimate personalization with a state of the art longitudinal data predictive analytics. Certain formulations described herein are unique, combinatory and synergistic. Secured by high-tech proprietary system, there are unlimited potentials using AQT technology including but not limited to 3-D printing of a biodegradable micro chips that can be delivered via injection, AQT or any other possible route.